MD, University of Missouri-Columbia School of Medicine, 1986
Residency:
Neurology, Hahnemann (Drexel University College of Medicine, Pennsylvania), 1990
Fellowship:
Movement Disorders, Baylor College of Medicine (Texas), 1991
Clinical Interests:
Movement disorders; Parkinson's disease and other Parkinsonian disorders; generalized and focal dystonias; Huntington's disease; Lewy body disease; myoclonus; restless legs syndrome; progressive supranuclear palsy; corticobasal ganglionic degeneration; multiple-system atrophy; Shy-Drager syndrome;
spasmodic torticollis; tremor and tic disorders; botulinum toxin injections; deep brain stimulation implantation
Research Interests:
Mark Stacy has clinical trial efforts concentrated on Neuroprotective and Neuro-regenerative therapies in PD, and developing biomarkers for early diagnosis in PD. He has extensive experience with Glial Derived Neurotrophic Factor (GDNF), neuroimmunophyllins (GPI-1046, AMG-474), jnk inhibitors (CEP-1347, TCH-346), and viral vectors (Ceregene). His independent research interests in Parkinson’s disease include motor and non-motor symptoms of wearing off, and pathological gambling and other impulse control disorders. He has published more than 100 manuscripts in the areas of PD, dystonia, tremor and other movement disorders. He is also the editor of The Handbook of Dystonia.